Schrodinger (SDGR) Q2 FY26 earnings call

Schrodinger delivered a strong Q2 FY26, marked by robust ACV growth and the official launch of Bunsen, its agentic AI co-scientist, which is already seeing adoption by key collaborators like Bristol Myers Squibb. The company is successfully executing its strategy to expand platform usage and unlock new budgets through product innovation and a shift to hosted licensing, while maintaining disciplined expense management. This quarter's results reflect the increasing industry recognition of computationally driven drug discovery.